DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Lesch-Nyhan syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLesch-Nyhan syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lesch-nyhan syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
hypoxanthine phosphoribosyltransferase 1 (HPRT1) — HPRT1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3~{r},4~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5HIA · 1.773 Å · ligand [3-[(3~{R},4~{R})-3-(2-azanyl-6-oxidanylidene-1~{H}-purin-9-yl)-4-[(2~{S})-2-oxidanyl-2-phosphono-ethoxy]pyrrolidin-1-y
l]-3-oxidanylidene-propyl]phosphonic acid (YPG). Experimental structure, not a prediction.
What the evidence adds up to
Lesch-Nyhan syndrome is an X-linked disease caused by deficiency of hypoxanthine phosphoribosyltransferase, an enzyme in the purine salvage pathways. It is characterised by severe gout, choreoathetosis, self-mutilatory behaviour and mental retardation. A 2018 case report describes an eight-month-old child presenting with respiratory symptoms and self-mutilation who was ultimately diagnosed with the syndrome. A 2013 case report describes an infant with motor delay, spasticity, dystonia, and crystalluria; treatment with allopurinol at 12 mg/kg of body weight per 24 hours reduced serum hyperuricemia to values below 7 mg/dl. Management includes drugs against hyperuricemia, measures to prevent self-mutilation and behavioural therapy.
A 2014 study reported the effects of intrathecal baclofen therapy on three patients who no longer received benefit from previous therapies. The treatment ameliorated motor symptoms and, unexpectedly, also improved behavioural components. The authors suggest this may involve a functional interaction between baclofen and dopamine, complemented by an anxiolytic effect. They provide a rationale for the use of intrathecal baclofen administration in Lesch-Nyhan syndrome, but note that current therapies are off-label and experimental, often leading to inconsistent outcomes.
A 1992 paper describes the derivation of mice genetically deficient in hypoxanthine phosphoribosyltransferase, intended to help elucidate the pathogenesis of the neurological abnormality. Previously, models using drug administration to mimic the disorder had to suffice.
What is still missing is any controlled trial data for intrathecal baclofen — the 2014 report is an uncontrolled observation in three patients. No therapy has been shown to alter the neurological or behavioural core of the disease beyond symptom management. Patient stratification by genetic or clinical subtype is absent from these reports, and funding for definitive trials in this ultra-rare condition remains scarce.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Internal Medicine · 1972 · 79 citations
Clinical Features of the Lesch-Nyhan Syndrome
AbstractLesch-Nyhan syndrome is characterized clinically by mental retardation, choreoathetosis, spastic cerebral palsy, and aggressive, self-mutilating behavior. It is transmitted as an X-linked excessive character in which the primary expression of the mutant gene is in the activity of the enzyme hypoxanthine guanine phosphoribosyltransferase (HGPRT). Metabolically, the disorder is characterized by hyperuricemia and increased amounts of uric acid in the urine. There is enormous overproduction of purine de novo. Treatment with allopurinol therapy is effective in the management of those aspects of the disease that are common to this condition and gout in the adult. Treatment is not available which is effective against the cerebral manifestations of the disease.
Journal of Inherited Metabolic Disease · 1992 · 19 citations
Mouse models of hypoxanthine phosphoribosyltransferase deficiency
AbstractLesch--Nyhan syndrome is an X-linked disease caused by the deficiency of hypoxanthine phosphoribosyltransferase, an enzyme involved in the purine salvage pathways. It is characterized by severe gout, choreoathetosis, self-mutilatory behaviour and mental retardation. The derivation of mice genetically deficient in this enzyme may help to elucidate the pathogenesis of the neurological abnormality where previously models using drug administration to mimic the disorder have had to suffice.
Orphanet Journal of Rare Diseases · 2014 · 18 citations · open access
Treatment of motor and behavioural symptoms in three Lesch-Nyhan patients with intrathecal baclofen
AbstractCurrent therapies for the Lesch-Nyhan Syndrome (OMIM: 300322) are off-label and experimental, often leading to inconsistent outcomes. We here report the effects of an intrathecal baclofen therapy, carried out at the Scientific Institute Eugenio Medea (Lecco, Italy), on three patients who no longer received benefit from previous therapies. This treatment, as expected, ameliorated the motor symptoms and, unexpectedly, it also improved behavioural components. This result may involve a functional interaction between baclofen and dopamine, complemented by an anxiolytic effect. Our observations provide the rationale for the use of intrathecal baclofen administration in the therapy of the Lesch-Nyhan Syndrome.
International Journal of Research in Medical Sciences · 2018 · 2 citations · open access
Lesch-Nyhan syndrome: case brief of a rare disease
AbstractLesch-Nyhan Syndrome is a rare X- linked disease due to absence of HPRT enzyme. It leads to hyperuricemia, gout, renal failure, neurological and behavioural disorders, including compulsive self-mutilation. Management includes drugs against hyperuricemia, measures to prevent self-mutilation and behavioural therapy. This case is that of an eight months old child coming for respiratory symptoms and self-mutilation, who was ultimately diagnosed with Lesch- Nyhan syndrome.
Niemowlę z opóźnionym rozwojem psychoruchowym i pomarańczowymi kryształkami na pieluszce – opis przypadku zespołu Lescha i Nyhana
AbstractLesch-Nyhan syndrome is a rare inborn error of metabolism with very poor prognosis. Patients vary in many ways but all seem to have impairments to some degree in uric acid metabolism, motor development, and behavior. A careful evaluation is essential toward making the appropriate diagnosis. A case of infant with motor delay, spasticity, dystonia, and crystalluria is reported. Treatment based on allopurinal (12 mg/kg of body weight/24 h) reduced serum hyperuricemia to values < 7 mg/dl.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
